| abstract |
The compounds of formula (I) are useful in the treatment of a disease responsive to modulation of CRTH2 receptor activity, such as asthma, rhinitis, allergic airway syndrome and allergic rhinobronchitis; and X denotes -S-, -O-, -N = N-, -NRy-, -CR = CR-, -CR = N-, where R and R are independently hydrogen or C-C1-6alkyl; A represents a carboxyl group —COOH or a bioisostere of a carboxyl group; Ar and Ar rings, each independently, are phenyl or a 5 or 6 membered monocyclic heteroaryl ring or a bicyclic ring system consisting of a 5 or 6 membered carbocyclic or heterocyclic ring which is benzofused or fused with 5 or 6 a monocyclic heteroaryl ring member, wherein said ring or ring system may be substituted; ring B has the meanings given for Ar and Ar, or denotes optionally substituted N-pyrrolidinyl, N-piperidinyl or N-azepinyl; s is 0 or 1; L1, L2 and L4 are linker radicals defined in the description; Q and Q are the substituents indicated in the description. |